A rising prevalence of cystic fibrosis globally, research and development activities undertaken by key players, and favorable initiatives undertaken by nonprofit organizations are expected to boost the market over the forecast period.
The rising prevalence of CF indicates the rising demand for treatment alternatives, thereby uplifting the market.
The key players operating in this market in collaboration with nonprofit organisations focus on the development of novel therapeutics for treatment. Some of the drugs that are under clinical studies are VX-445 + tezacaftor + ivacaftor, PTI-428, QR-010, AZD5634, and POL6014.
Favourable initiatives taken by regional and national nonprofit organizations is one of the key factors propelling growth.
These initiatives ensure support to CF patients. These organizations aid in research and development activities of these therapeutics and help improve the quality of life of these patients.
For instance, North American Cystic Fibrosis Conference (NACFC) was formed in 1986 to provide a collaborative and educational forum to CF professionals to share advances in R/D related to CF therapeutics.
The global CF therapeutics market size was estimated at 3,560.5 m in 2016 and is expected to grow at a CAGR of 16.7% from 2017 to 2025.
The CFTR modulator segment emerged as the largest segment in 2016 and the same segment is anticipated to witness fastest growth over the next 8 years owing to the approval of CFTR modulator, Orkambi and the presence of various investigational compounds under the pipeline.
Oral route of administration emerged as the largest segment with revenue of USD 2,266.4m due to the ease of administration and convenience.
North America accounted for the largest market share owing to the presence of Caucasian descents in this region. Improved healthcare infrastructure, reimbursements, and initiatives undertaken by the nonprofit organizations is expected to propel the market over forecast period,
The key players include AbbVie Inc., F. Hoffmann-La Roche Ltd.; Gilead, Novartis AG, Vertex Pharmaceuticals Inc., AIT (Advanced Inhalation Therapies), Alaxia, Teva Pharmaceutical Industries Ltd, Merck and Co. Inc., Alcresta Therapeutics Inc., Allergan, and AstraZeneca.
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial